Halozyme Therapeutics Inc (HALO)

[OncoJock]

Agree with this analysis.

Also found myself wondering, while shaving this morning, what would happen if additional CMS guidance this fall reinforces Helen and Rob Davis' perspective that combining hyaluronidase with an old drug -- and changing the route of administration -- qualifies it as a new drug, thus resetting the clock (delaying) on when the Medicare price negotiations begin.

If adding a subQ version becomes widely perceived as a fountain of youth for Big Pharma's most important cash cows, and Merck blazes the trail in a very visible manner with a subQ version of its blockbuster Keytruda, wouldn't many other Pharmas of all sizes like to follow suit and sign deals with Halozyme, or develop their own subQ version in-house, to prevent having to negotiate downward on price with CMS? And to stave off competition from those annoyingly cheap and pesky biosimilars?

I realize this is a very bullish case, but we can dream can't we?

-- OJ